Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Participants will be randomized to drug or placebo for 12 months
In Study 8, at Week 72, the body weight was missing for 5.5%, 6.0% and 15.0% of patients randomized to WEGOVY 7.2 mg, WEGOVY 2.4 mg and placebo, respectively
John Lekkas GMC Registration: 7448560 Dr John Lekkas is a GMC registered medical doctor with a specialist PhD, and is a global leading expert in weight loss and aesthetic medicine
Women who are still experiencing significant sexual dysfunction after six months on a stable dose should consult their provider, as this may warrant intervention or medication adjustment
Focusing on individuals who had been treated with semaglutide 2.4 mg for 1 year introduced a potential selection bias, as these individuals were more likely to have experienced benefits and may have demonstrated higher adherence to the medication
Kynoselen protects muscles and delays the onset of Muscle fatigue
